Mathews Adera, MD
VP, Clinical Development
Mathews is a physician, medical physiologist and clinical research professional with 20+ years’ experience in clinical practice, clinical research, biomedical research and tertiary college teaching. Mathews has a wealth of experience across a number of therapeutic areas including lysosomal disorders (Pompe, Fabry and Gaucher), respiratory diseases, oncology, transplantation, immunology and CNS.
While at Amicus Therapeutics, he was head of the Pompe clinical development program and was responsible for authoring and contributing to the drug development strategy for all Pompe clinical programs. There, Mathews was also the project physician and clinical team lead for the Pompe, Fabry and Gaucher clinical programs. He has served in similar roles at Ovid Therapeutics, Albireo Pharma, Braeburn Pharmaceutical and Acorda Therapeutics.
He received his medical degree at the University of Nairobi.
CloseToday is MPS Awareness Day (MPS II is also known as Hunter syndrome) and we want to recognize the incredible work that patient advocacy groups do year-round to support the Hunter syndrome community.
Learn more about Hunter syndrome and the patient advocacy groups’ efforts here: